Semaglutide, with its seven-day half-life, has the most residual medication in your system at injection time
In a first-of-its-kind U.S
At least 21 lawsuits are currently included in the new proceeding, brought by former GLP-1 users who allege the drugs caused non-arteritic anterior ischemic optic neuropathy (NAION)
That might offer a good target for future pharmacotherapies, she suggested
GLP-1 medications currently named in lawsuits and regulatory investigations include: Individuals who experienced hospitalization, emergency treatment, surgery, prolonged gastrointestinal symptoms, or medically documented vision loss after taking these medications may have grounds to pursue legal action
NEFA, Non-esterified fatty acids